VJHemOnc is committed to improving our service to you

ICML 2019 | Ibrutinib-rituximab safe and effective in the frontline for elderly MCL

VJHemOnc is committed to improving our service to you

Preetesh Jain

Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the Phase II trial (NCT01880567) investigating the combination of ibrutinib with rituximab for the frontline treatment of elderly patients with mantle cell lymphoma (MCL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter